CBG forms from the enzymatic conversion of cannabigerolic acid (CBGA), the first cannabinoid acid produced in the cannabis plant. CBGA is subsequently acted on by specific synthase enzymes , THCA synthase, CBDA synthase, and CBCA synthase , to yield the acidic precursors of THC, CBD, and CBC respectively. Because most CBGA is diverted into these downstream pathways, mature cannabis plants typically accumulate CBG at concentrations below 1% by dry weight, which is why it is sometimes described as a "minor" cannabinoid despite its central biosynthetic role.
Chemically, CBG is a terpenophenolic compound with the molecular formula C₂₁H₃₂O₂ and a molecular weight of 316.48 g/mol. Unlike THC, CBG does not bind with high affinity to the CB₁ receptor, and therefore does not produce the psychoactive effects associated with THC. Research published in journals including the British Journal of Pharmacology has characterised CBG as a partial agonist at CB₁ and CB₂ receptors, a moderate antagonist at TRPM8 channels, and an inhibitor of the endocannabinoid reuptake transporter for anandamide (AEA), though the functional significance of these interactions in humans remains under active investigation.
In Australia, CBG derived from cannabis is regulated under the Poisons Standard 2015 (the SUSMP). Cannabis-derived CBG preparations are captured under the Schedule 4 (prescription-only) or Schedule 8 (controlled drug) classifications depending on concentration and formulation, consistent with the Therapeutic Goods Administration's broader framework for cannabis-derived substances. Isolated or synthetic CBG is not currently listed as an approved active ingredient in any registered therapeutic good on the Australian Register of Therapeutic Goods (ARTG) as of mid-2025; access for clinical or research purposes may proceed via the TGA's Special Access Scheme (SAS) or Authorised Prescriber pathway.
Preclinical research on CBG is ongoing, with in-vitro and animal studies examining its pharmacological profile across several receptor systems. As with many minor cannabinoids, the current evidence base consists largely of preclinical data; robust, placebo-controlled human clinical trials remain limited, and no conclusions about efficacy or safety in humans can be drawn from the available literature.
Sources: